Overview of regulation of dietary supplements in the USA and issues of adulteration with phenethylamines (PEAs)

Drug Testing and Analysis

Volumn 9, Issue 3, 2017, Pages 500-517

  Pawar, Rahul S ^a   Grundel, Erich ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

adulteration; dietary supplements; DSHEA; new dietary ingredient; phenethylamine

Indexed keywords

ACCIDENT PREVENTION; FINITE DIFFERENCE METHOD; FOOD ADDITIVES; NUTRITION; VITAMINS;

ADULTERATION; ADVERSE EVENTS; DIETARY SUPPLEMENT HEALTH AND EDUCATION ACT OF 1994; FEDERAL FOOD DRUG AND COSMETIC ACT; FOOD AND DRUG ADMINISTRATION; GOOD MANUFACTURING PRACTICES; NATURALLY OCCURRING; NEW DIETARY INGREDIENT; PHENETHYLAMINES; US FOOD AND DRUG ADMINISTRATION;

DIETARY SUPPLEMENTS;

1,3 DIMETHYLAMINE; 1,3 DIMETHYLBUTYLAMINE; AEGELINE; ALPHA ETHYL PHENETHYLAMINE; AMINOALCOHOL; ANTIOBESITY AGENT; BETA METHYLPHENETHYLAMINE; DIMETHYLAMINE; FENFLURAMINE; LORCASERIN; METHYLSYNEPHRINE; PHENETHYLAMINE DERIVATIVE; SIBUTRAMINE; UNCLASSIFIED DRUG;

ACACIA; ADULTERATION; DENDROBIUM; DIETARY SUPPLEMENT; DRUG SAFETY; EPHEDRA; FOOD AND DRUG ADMINISTRATION; GOOD MANUFACTURING PRACTICE; GOVERNMENT REGULATION; HEALTH CARE POLICY; HUMAN; NONHUMAN; NUTRITIONAL SUPPORT; REGISTRATION; REVIEW; SOUR ORANGE; STANDARDIZATION; UNITED STATES; ADVERSE EFFECTS; ANALYSIS; DRUG CONTAMINATION; DRUG CONTROL; QUALITY CONTROL;

ANTI-OBESITY AGENTS; DIETARY SUPPLEMENTS; DRUG AND NARCOTIC CONTROL; DRUG CONTAMINATION; HUMANS; PHENETHYLAMINES; QUALITY CONTROL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84973365094     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1980     Document Type: Review

References (177)

1. A. Lindstrom, C. Ooyen, M. E. Lynch, M. Blumenthal, K. Kawa. Sales of herbal dietary supplements increase by 7.9% in 2013, marking a decade of rising sales: Turmeric supplements climb to top ranking in natural channel. Herbalgram. 2014, (103), 52.
2. Food and Drug Administration. CFSAN Constituent Update. Available at: http://www.fda.gov/Food/NewsEvents/ConstituentUpdates/ucm381317.htm [14 December 2015].
3. R. L. Bailey, J. J. Gahche, P. E. Miller, P. R. Thomas, J. T. Dwyer. Why US adults use dietary supplements. JAMA Intern. Med. 2013, 173, 355.
4. L. Vaclavik, A. J. Krynitsky, J. I. Rader. Mass spectrometric analysis of pharmaceutical adulterants in products labeled as botanical dietary supplements or herbal remedies: a review. Anal. Bioanal. Chem. 2014, 406, 6767.
5. Food and Drug Administration. Tainted Products Marketed as Dietary Supplements_CDER. Available at: http://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=tainted_supplements_cder [1 March 2016].
6. H. Geyer, M. K. Parr, K. Koehler, U. Mareck, W. Schänzer, M. Thevis. Nutritional supplements cross-contaminated and faked with doping substances. J. Mass Spectrom. 2008, 43, 892.
7. 103d Congress. Public Law 103-417. Dietary Supplement Health and Education Act of 1994. Available at: http://www.gpo.gov/fdsys/pkg/STATUTE-108/pdf/STATUTE-108-Pg4325.pdf [1 July 2015].
8. Food and Drug Administration. Federal Register Vol. 65, No. 4, 1000 Regulations on Statements Made for Dietary Supplements Concerning the Effect of the Product on the Structure or Function of the Body. Available at: http://www.gpo.gov/fdsys/pkg/FR-2000-01-06/pdf/00-53.pdf [2 December 2015].
9. Food and Drug Administration. Guidance for industry: Substantiation for dietary supplement claims made under section 403(r) (6) of the Federal Food, Drug, and Cosmetic Act. Available at: http://www.fda.gov/food/guidanceregulation/guidancedocumentsregulatoryinformation/dietarysupplements/ucm073200.htm [14 December 2015].
10. Food and Drug Administration. Federal Register Vol. 72, No. 121, 34752. Current good manufacturing practice in manufacturing, packaging, labeling, or holding operations for dietary supplements. Available at: http://www.gpo.gov/fdsys/pkg/FR-2007-06-25/pdf/07-3039.pdf [01 July 2015].
11. 107th Congress. Public Law 107-188. Public Health Security and Bioterrorism Preparedness and Response Act of 2002. Available at: http://www.gpo.gov/fdsys/pkg/PLAW-107publ188/pdf/PLAW-107publ188.pdf [01 July 2015].
12. Food and Drug Administration. Federal Register Vol. 68, No. 197, 58894 Registration of Food Facilities Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002. Available at: http://www.gpo.gov/fdsys/pkg/FR-2003-10-10/pdf/03-25849.pdf [17 June 2015].
13. Food and Drug Administration. Title 21 / Chapter 9 / Subchapter VII / Part H / § 379aa-1 Available at: http://www.gpo.gov/fdsys/pkg/USCODE-2010-title21/pdf/USCODE-2010-title21-chap9-subchapVII-partH-sec379aa-1.pdf [17 June 2015].
14. Public Law 109-462. To amend the Federal Food, Drug, and Cosmetic Act with respect to serious adverse event reporting for dietary supplements and nonprescription drugs, and for other purposes. Available at: www.gpo.gov/fdsys/pkg/PLAW-109publ462/html/PLAW-109publ462.htm [2 December 2015].
15. FDA Food Safety Modernization Act. Available at: http://www.gpo.gov/fdsys/pkg/PLAW-111publ353/pdf/PLAW-111publ353.pdf [1 July 2015].
16. FDA. Annual Report to Congress on the Use of Mandatory Recall Authority - 2014. Available at: http://www.fda.gov/Food/GuidanceRegulation/FSMA/ucm442802.htm [2 December 2015].
17. Food and Drug Administration. Draft Guidance for Industry: Questions and Answers Regarding Mandatory Food Recalls. Available at: http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/ucm445428.htm [2 December 2015].
18. A. Abdel-Rahman, N. Anyangwe, L. Carlacci, S. Casper, R. P. Danam, E. Enongene, G. Erives, D. Fabricant, R. Gudi, C. J. Hilmas, F. Hines, P. Howard, D. Levy, Y. Lin, R. J. Moore, E. Pfeiler, T. S. Thurmond, S. Turujman, N. J. Walker. The safety and regulation of natural products used as foods and food ingredients. Toxicol. Sci. 2011, 123, 333.
19. Food and Drug Administration. Federal Register Vol. 61, No. 189, 50774. Proposed Rule, Premarket Notification for a New Dietary Ingredient. Available at: https://www.gpo.gov/fdsys/pkg/FR-1996-09-27/pdf/96-24752.pdf [14 December 2015].
20. Food and Drug Administration. Premarket Notification for a New Dietary Ingredient, 21CFR190.6. Available at: www.gpo.gov/fdsys/pkg/FR-1997-09-23/pdf/97-24737.pdf [1 July 2015].
21. Food and Drug Administration. Draft Guidance for Industry: Dietary Supplements: New Dietary Ingredient Notifications and Related Issues. Available at: http://www.fda.gov/food/guidanceregulation/guidancedocumentsregulatoryinformation/dietarysupplements/ucm257563.htm [17 June 2015].
22. Food and Drug Administration. Federal Register Vol. 69, No. 28. Final Rule Declaring Dietary Supplements Containing Ephedrine Alkaloids Adulterated Because They Present an Unreasonable Risk. Available at: http://www.gpo.gov/fdsys/pkg/FR-2004-02-11/pdf/04-2912.pdf [1 July 2015].
23. Food and Drug Administration. Enforcement Report. Available at: http://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Event-Detail.cfm?action=detail&id=61842&w=07182012& [8 June 2015].
24. R. S. Pawar, H. Tamta, J. Ma, A. J. Krynitsky, E. Grundel, W. G. Wamer, J. I. Rader. Updates on chemical and biological research on botanical ingredients in dietary supplements. Anal. Bioanal. Chem. 2013, 405, 4373.
25. P. A. Cohen. DMAA as a dietary ingredient-reply. JAMA Intern. Med. 2013, 173, 595.
26. J. V. Rodricks, M. H. Lumpkin. DMAA as a dietary ingredient. JAMA Intern. Med. 2013, 173, 594.
27. Department of Defence. 1,3 Dimethylamylamine (DMAA) Safety Review Panel. Available at: http://fhpr.dhhq.health.mil/Libraries/pdf/Report_of_the_DoD_DMAA_Safety_Review_Panel_2013.sflb.ashx [2 December 2015].
28. P. Gee, S. Jackson, J. Easton. Another bitter pill: a case of toxicity from DMAA party pills. N. Z. Med. J. 2010, 123, 124.
29. P. Gee, C. Tallon, N. Long, G. Moore, R. Boet, S. Jackson. Use of recreational drug 1,3 Dimethylamylamine (DMAA) [corrected] associated with cerebral hemorrhage. Ann. Emerg. Med. 2012, 60, 431.
30. L. V. Karnatovskaia, J. C. Leoni, M. L. Freeman. Cardiac arrest in a 21-year-old man after ingestion of 1,3-DMAA-containing workout supplement. Clin. J. Sport Med. 2015, 25, e23.
31. J. R. Archer, P. I. Dargan, A. M. Lostia, J. van der Walt, K. Henderson, N. Drake, S. Sharma, D. M. Wood, C. J. Walker, A. T. Kicman. Running an unknown risk: a marathon death associated with the use of 1,3-dimethylamylamine (DMAA). Drug Test. Anal. 2015, 7, 433.
32. Food and Drug Administration. DMAA in Dietary Supplements. Available at: http://www.fda.gov/Food/DietarySupplements/QADietarySupplements/ucm346576.htm [18 June 2015].
33. Food and Drug Administration. Warning Letter. Available at: http://www.fda.gov/iceci/enforcementactions/warningletters/2014/ucm418717.htm [08 April 2016].
34. Food and Drug Administration. Warning letter. Available at: http://www.fda.gov/iceci/enforcementactions/warningletters/2013/ucm369317.htm [08 April 2016].
35. Food and Drug Administration. Warning Letter. Available at: http://www.fda.gov/iceci/enforcementactions/warningletters/2013/ucm362465.htm [08 April 2016].
36. Food and Drug Administration. Stimulant Potentially Dangerous to Health, FDA Warns. Available at: http://www.fda.gov/forconsumers/consumerupdates/ucm347270.htm [25 June 2015].
37. Food and Drug Administration. Response Letter to USP Labs LLC Concerning DMAA. Available at: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofFoods/CFSAN/CFSANFOIAElectronicReadingRoom/ucm350199.htm [15 December 2015].
38. P. A. Cohen, J. C. Travis, B. J. Venhuis. A synthetic stimulant never tested in humans, 1,3-dimethylbutylamine (DMBA), is identified in multiple dietary supplements. Drug Test. Anal. 2015, 7, 83.
39. B. Avula, M. Wang, S. Sagi, P. A. Cohen, Y. H. Wang, P. Lasonkar, A. G. Chittiboyina, W. Feng, I. A. Khan. Identification and quantification of 1,3-dimethylbutylamine (DMBA) from Camellia sinensis tea leaves and dietary supplements. J. Pharm. Biomed. Anal. 2015, 115, 159.
40. Food and Drug Administration. DMBA in Dietary Supplements. Available at: http://www.fda.gov/Food/DietarySupplements/QADietarySupplements/ucm444719.htm [15 December 2015].
41. T. A. Smith. Phenethylamine and related compounds in plants. Phytochemistry. 1977, 16, 9.
42. J. Khan, T. Kennedy, D. Christian, Jr. Basic Principles of Forensic Chemistry. Humana Press: New York, USA, 2012.
43. S. Freeman, J. F. Alder. Arylethylamine psychotropic recreational drugs: a chemical perspective. Eur. J. Med. Chem. 2002, 37, 527.
44. G. Lau, D. S. Lo, Y. J. Yao, H. T. Leong, C. L. Chan, S. S. Chu. A fatal case of hepatic failure possibly induced by nitrosofenfluramine: a case report. Med. Sci. Law. 2004, 44, 252.
45. J. Lee, S. Choe, H. Choi, S. Heo, E. Kim, H. Kim, E. Bang, H. Chung. Identification of N-ethyl--ethylphenethylamine in crystalline powder seized for suspected drug trafficking: a research chemical or a new designer drug? Forensic Toxicol. 2013, 31, 54.
46. S. E. Lakhan, A. Kirchgessner. Prescription stimulants in individuals with and without attention deficit hyperactivity disorder: misuse, cognitive impact, and adverse effects. Brain Behav. 2012, 2, 661.
47. A. S. Christophersen. Amphetamine designer drugs - an overview and epidemiology. Toxicol. Lett. 2000, 112-113, 127.
48. J. M. Prosser, L. S. Nelson. The toxicology of bath salts: a review of synthetic cathinones. J. Med. Toxicol. 2012, 8, 33.
49. World Anti-Doping Agency. World Anti-doping Code. The 2014 Prohibited List. Available at: https://wada-main-prod.s3.amazonaws.com/resources/files/WADA-Revised-2014-Prohibited-List-EN.PDF [29 June 2015].
50. The World Anti-Doping Agency. The 2015 Prohibited List. International Standard. Available at: https://wada-main-prod.s3.amazonaws.com/resources/files/wada-2015-prohibited-list-en.pdf [2 December 2015].
51. G. Sigmund, J. Dib, L. Tretzel, T. Piper, C. Bosse, W. Schanzer, M. Thevis. Monitoring 2-phenylethanamine and 2-(3-hydroxyphenyl)acetamide sulfate in doping controls. Drug Test. Anal. 2015. DOI:10.1002/dta.1909.
52. D. S. Seigler. Phytochemistry of Acacia- sensu lato. Biochem. Sys. Ecol. 2003, 31, 845.
53. S. Rastogi, M. M. Pandey, A. K. Rawat. An ethnomedicinal, phytochemical and pharmacological profile of Desmodium gangeticum (L.) DC. and Desmodium adscendens (Sw.) DC. J. Ethnopharmacol. 2011, (136), 283.
54. NIH, The Dietary Supplement Label Database. Available at: http://www.dsld.nlm.nih.gov/dsld/ [22 June 2015].
55. R. S. Pawar, E. Grundel, A. R. Fardin-Kia, J. I. Rader. Determination of selected biogenic amines in Acacia rigidula plant materials and dietary supplements using LC-MS/MS methods. J. Pharm. Biomed. Anal. 2014, 88, 457.
56. S. J. Stohs, H. G. Preuss, M. Shara. A review of the receptor-binding properties of p-synephrine as related to Its pharmacological effects. Oxid. Med. Cell. Longev. 2011Article ID 482973.
57. J. Palamar. How ephedrine escaped regulation in the United States: a historical review of misuse and associated policy. Health Policy. 2011, 99, 1.
58. C. A. Haller, N. L. Benowitz. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N. Engl. J. Med. 2000, 343, 1833.
59. Food and Drug Administration. FDA issues regulation prohibiting sale of dietary supplements containing ephedrine alkaloids and reiterates its advice that consumers stop using these products. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108242.htm [18 June 2015].
60. Casewatch. Utah Appeals Court Upholds FDA Ephedra Ban. Available at: http://www.casewatch.org/fda/court/ephedra/utah2.shtml [18 June 2015].
61. S. Ghosh, A. Dutt. The chemical examination of Sida cordifolia. Linn. J. Indian Chem. Soc. 1930, 7, 825.
62. A. Prakash, R.K. Varma, S. Ghosal. Alkaloid constituents of Sida acuta, S. humilis, S. rhombifolia and S. spinosa. Planta Med. 1981, 43, 384.
63. S. Khatoon, M. Srivastava, A. K. S. Rawat, S. Mehrotra. HPTLC method for chemical standardization of Sida species and estimation of the alkaloid ephedrine. J. Planar Chromatogr. 2005, 18, 364.
64. A. Chatterjee, S. Kumar, S. K. Chattopadhyay. A validated HPLC-PDA method for identification and quantification of two bioactive alkaloids, ephedrine and cryptolepine, in different Sida species. Biomed. Chromatogr. 2013, 27, 1720.
65. A. N. Jadhav, R. S. Pawar, B. Avula, I. A. Khan. Ecdysteroid glycosides from Sida rhombifolia L. Chem. Biodivers. 2007, 4, 2225.
66. E. Marchei, M. Pellegrini, R. Pacifici, P. Zuccaro, S. Pichini. A rapid and simple procedure for the determination of ephedrine alkaloids in dietary supplements by gas chromatography-mass spectrometry. J. Pharm. Biomed. Anal. 2006, 41, 1633.
67. H. Oshio, M. Tsukui, T. Matsuoka. Isolation of l-ephedrine from 'pinelliae tuber'. Chem Pharm Bull (Tokyo). 1978, 26, 2096.
68. M. Moriyasu, M. Endo, R. Kanazawa, Y. Hashimoto, A. Kato, M. Mizuno. High-performance liquid chromatographic determination of organic substances by metal chelate derivatization. III. Analysis of Ephedra bases. Chem. Pharm. Bull. 1984, 32, 744.
69. M. Zell-Kanter, M. A. Quigley, J. B. Leikin. Reduction in ephedra poisonings after FDA ban. N. Engl. J. Med. 2015, 372, 2172.
70. D. B. Allison, G. Cutter, E. T. Poehlman, D. R. Moore, S. Barnes. Exactly which synephrine alkaloids does Citrus aurantium (bitter orange) contain? Int. J. Obes. (Lond). 2005, 29, 443.
71. C. M. Brown, J. C. McGrath, J. M. Midgley, A. G. Muir, J. W. O'Brien, C. M. Thonoor, C. M. Williams, V. G. Wilson. Activities of octopamine and synephrine stereoisomers on alpha-adrenoceptors. Br. J. Pharmacol. 1988, 93, 417.
72. R. Jordan, J. M. Midgley, C. M. Thonoor, C. M. Williams. Beta-adrenergic activities of octopamine and synephrine stereoisomers on guinea-pig atria and trachea. J. Pharm. Pharmacol. 1987, 39, 752.
73. I. Stewart, W. F. Newhall, G. J. Edwards. The isolation and identification of l-synephrine in the leaves and fruit of citrus. J. Biol. Chem. 1964, 239, 930.
74. B. Avula, S. K. Upparapalli, A. Navarrete, I. A. Khan. Simultaneous quantification of adrenergic amines and flavonoids in C. aurantium, various Citrus species, and dietary supplements by liquid chromatography. J. AOAC Int. 2005, 88, 1593.
75. F. Pellati, S. Benvenuti. Fast high-performance liquid chromatography analysis of phenethylamine alkaloids in Citrus natural products on a pentafluorophenylpropyl stationary phase. J. Chromatogr. A. 2007, 1165, 58.
76. S. J. Stohs, H. G. Preuss, M. Shara. A review of the human clinical studies involving Citrus aurantium (bitter orange) extract and its primary protoalkaloid p-synephrine. Int. J. Med. Sci. 2012, 9, 527.
77. G. Calapai, F. Firenzuoli, A. Saitta, F. Squadrito, M. R. Arlotta, G. Costantino, G. Inferrera. Antiobesity and cardiovascular toxic effects of Citrus aurantium extracts in the rat: a preliminary report Fitoterapia. 1999, 70, 586.
78. D. K. Hansen, N. I. George, G. E. White, L. S. Pellicore, A. Abdel-Rahman, D. Fabricant. Physiological effects following administration of Citrus aurantium for 28 days in rats. Toxicol. Appl. Pharmacol. 2012, 261, 236.
79. D. K. Hansen, N. I. George, G. E. White, A. Abdel-Rahman, L. S. Pellicore, D. Fabricant. Cardiovascular toxicity of Citrus aurantium in exercised rats. Cardiovasc. Toxicol. 2013, 13, 208.
80. Health Canada. Guidelines for the Use of Synephrine in Natural Health Products. Available at: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/prodnatur/legislation/docs/notice-synephrine-eng.pdf [19 June 2015].
81. NCCIH. Bitter Orange Available at: https://nccih.nih.gov/health/bitterorange#cautions [19 June 2015].
82. B. J. Camp, C. M. Lyman. The isolation of N-methyl beta-phenylethylamine from Acacia berlandieri. J. Am. Pharm. Assoc. Am. Pharm. Assoc. (Baltim). 1956, (45), 719.
83. J. S. Fitzgerald. Alkaloids of the Australian Leguminosae. Aust. J. Chem. 1964, 17, 160.
84. B. Camp, M. Norvell. The phenylethylamine alkaloids of native range plants. Econ. Bot. 1966, 20, 274.
85. B. A. Clement, C. M. Goff, T. D. A. Forbes. Toxic amines and alkaloids from Acacia rigidula. Phytochemistry. 1998, 49, 1377.
86. Food Standards Agency. Request for information from businesses: Acacia rigidula. Available at: https://www.food.gov.uk/sites/default/files/multimedia/pdfs/letter-acacia-rigidula.pdf [22 June 2015].
87. Foods Standards Agency. Foods Standards Agency. Available at: https://www.food.gov.uk/sites/default/files/multimedia/pdfs/letters/acacia-rigidula-interested-parties-letter.pdf [17 June 2015].
88. Food and Drug Administration., Warning Letter. Available at: http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2016/ucm489456.htm [08 April 2016].
89. Food and Drug Administration. Acacia rigidula in Dietary Supplements. Available at: http://www.fda.gov/Food/DietarySupplements/ProductsIngredients/ucm489921.htm [08 April 2016].
90. M. S. Baliga, H. P. Bhat, N. Joseph, F. Fazal. Phytochemistry and medicinal uses of the bael fruit (Aegle marmelos Correa): A concise review. Food Res. Int. 2011, 44, 1768.
91. D. I. Johnston, A. Chang, M. Viray, K. Chatham-Stephens, H. He, E. Taylor, L. L. Wong, J. Schier, C. Martin, D. Fabricant, M. Salter, L. Lewis, S. Y. Park. Hepatotoxicity associated with the dietary supplement OxyELITE Pro - Hawaii, 2013. Drug Test. Anal. 2015. DOI:10.1002/dta.1894.
92. Food and Drug Administration. Annual Report to Congress on the Use of Mandatory Recall Authority - 2014. Available at: http://www.fda.gov/Food/GuidanceRegulation/FSMA/ucm442802.htm [2 December 2015].
93. P.A. Cohen, C. Bloszies, C. Yee, R. Gerona. An amphetamine isomer whose efficacy and safety in humans has never been studied, beta-methylphenylethylamine (BMPEA), is found in multiple dietary supplements. Drug Test. Anal. 2015, DOI: 10.1002/dta.1793
94. I. Julius, B. Cohen, J. Marshall, H. E. Woodman. Disposition of the bonds of the quinquevalent nitrogen atom. J. Chem. Soc., Trans. 1915, 107, 887.
95. B. E. Graham, G. F. Cartland, E. H. Woodruff. Phenyl propyl and phenyl isopropyl amines. Ind. Eng. Chem. 1945, 37, 149.
96. A. D. Mosnaim, O. H. Callaghan, T. Hudzik, M. E. Wolf. Rat brain-uptake index for phenylethylamine and various monomethylated derivatives. Neurochem. Res. 2013, 38, 842.
97. A. D. Mosnaim, T. Hudzik, M. E. Wolf. Analgesic effects of beta-phenylethylamine and various methylated derivatives in mice. Neurochem. Res. 2014, 39, 1675.
98. 98 A. A. Boulton, G. B. Baker, W. G. Dewhurst, M. Sandler, A. D. Mosnaim, M. E. Wolf, E. A. Zeller. Neurobiology of the Trace Amines, Humana Press 1984, pp. 299.
99. UK Anti-Doping. Rule Violations. Available at: http://www.ukad.org.uk/anti-doping-rule-violations/current-violations/ [23 June 2015].
100. International Canoe Federation. CAS decision in the Jan Sterba case - ICF statement. Available at: http://www.canoeicf.com/icf/NewsGallery/News-Archive/August-2012/CAS-Decision-Jan-Sterba.html [23 June 2015].
101. P. Cholbinski, M. Wicka, K. Kowalczyk, A. Jarek, P. Kaliszewski, A. Pokrywka, E. Bulska, D. Kwiatkowska. Detection of beta-methylphenethylamine, a novel doping substance, by means of UPLC/MS/MS. Anal. Bioanal. Chem. 2014, 406, 3681.
102. D. Kwiatkowska, M. Wojtowicz, A. Jarek, C. Goebel, K. Chajewska, E. Turek-Lepa, A. Pokrywka, R. Kazlauskas. N,N-dimethyl-2-phenylpropan-1-amine - new designer agent found in athlete urine and nutritional supplement. Drug Test. Anal. 2014. DOI:10.1002/dta.1741.
103. A. W. Weston, D. A. Wayne, C. M. Suter. The condensation of unsaturated amines with aromatic compounds. The preparation of β-substituted phenethylamines. J. Am. Chem. Soc. 1943, 65, 674.
104. P. A. Cohen, R. Zeijlon, R. Nardin, P. H. Keizers, B. Venhuis. Hemorrhagic stroke probably caused by exercise combined with a sports supplement containing beta-methylphenyl-ethylamine (BMPEA): a case report. Ann. Intern. Med. 2015, 162, 879.
105. Food and Drug Administration. BMPEA in Dietary Supplements. Available at: http://www.fda.gov/Food/DietarySupplements/QADietarySupplements/ucm443790.htm [15 December 2015].
106. Health Canada. 'Jetfuel Superburn' recalled after Health Canada tests find undeclared drug ingredients. Available at: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2014/43087r-eng.php [22 June 2015].
107. Food and Drug Administration. Orange Book. Available at: http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm [2 July 2015].
108. K. Pohl, W. Kriech. Therapy of orthostatic disorders of cardiovascular regulation. Placebo controlled double-blind study with oxilofrine. Fortschr. Med. 1991, 109, 685.
109. R. Domonjoz, A. Fleisch. The effect of circulatory-active drugs on veins. Arch. Exp. Pathol. Pharmakol. 1939, 192, 645.
110. C. Dupont, J. Wepierre, Y. Cohen, G. Valette. Comparative study of cardiovascular effects of ephedrine,p-hydroxyephedrine and p-hydroxyamphetamine on the dog. J. Pharmacol. 1972, 3, 85.
111. R. Boulu, J. R. Rapin, M. Lebas, C. Jacquot. Central effect of amphetamine, ephedrine and p-hydroxylated derivatives in the rat after unilateral lesion of nigrostriatal pathways. Psychopharmacologia. 1972, 26, 54.
112. M. Verho, V. Malerczyk, G. Kauert, H. Lorenz. Dose linearity and relative bioavailability testing of oxilofrine, a sympathicomimetic drug, in healthy volunteers. Int. J. Clin. Pharmacol. Res. 1988, 8, 211.
113. G. Kauert, C. Angermann, H. Lex, C. Spes. Clinical pharmacokinetics after a single oral dose of oxilofrine. Int. J. Clin. Pharmacol. Res. 1988, 8, 307.
114. WADA. The 2014 Prohibited List. Available at: https://wada-main-prod.s3.amazonaws.com/resources/files/WADA-Revised-2014-Prohibited-List-EN.PDF [29 June 2015].
115. A. Coghlan. Supplements fingered in sprinters' positive dope tests. Available at: http://www.newscientist.com/article/dn23868-supplements-fingered-in-sprinters-positive-dope-tests.html [15 December 2015].
116. B. Venhuis, P. Keizers, A. van Riel, D. de Kaste. A cocktail of synthetic stimulants found in a dietary supplement associated with serious adverse events. Drug Test. Anal. 2014, 6, 578.
117. Food and Consumer Product Safety Authority (NVWA). Security warning for slimmers and athletes: Don't take Dexaprine (Veiligheidswaarschuwing voor afvallers en sporters: slik geen Dexaprine). Available at: https://www.nvwa.nl/actueel/nieuws/nieuwsbericht/2036901/veiligheidswaarschuwing-voor-afvallers-en-sporters-slik-geen-dexaprine [08 April 2016].
118. F. Badoud, E. Grata, L. Perrenoud, L. Avois, M. Saugy, S. Rudaz, J. L. Veuthey. Fast analysis of doping agents in urine by ultra-high-pressure liquid chromatography-quadrupole time-of-flight mass spectrometry I. Screening analysis. J. Chromatogr. A. 2009, 1216, 4423.
119. E. Deconinck, T. Cauwenbergh, J. L. Bothy, D. Custers, P. Courselle, J. O. De Beer. Detection of sibutramine in adulterated dietary supplements using attenuated total reflectance-infrared spectroscopy. J. Pharm. Biomed. Anal. 2014, 100, 279.
120. J. Vaysse, S. Balayssac, V. Gilard, D. Desoubdzanne, M. Malet-Martino, R. Martino. Analysis of adulterated herbal medicines and dietary supplements marketed for weight loss by DOSY 1H-NMR. Food Addit. Contam. Part A Chem. Anal. Control Expo. Risk Assess. 2010, 27, 903.
121. Food and Drug Administration. Premarket notification for a New Dietery Ingredient: Betaphrine. Available at: http://www.fda.gov/ohrms/dockets/dockets/95s0316/95s-0316-rpt0258-04-SSPF-vol174.pdf [29 June 2015].
122. Food and Drug Administration. Response letter: NDI Notification for Betaphrine. Available at: http://www.fda.gov/ohrms/dockets/dockets/95s0316/95s-0316-rpt0258-02-vol174.pdf [29 June 2015].
123. T. R. Pilkington, R. D. Lowe, R. Foster, B. F. Robinson, A. Antonis. Effect of sympathomimetic compounds with beta-adrenergic effects on plasma free fatty acids in man. J. Lipid Res. 1966, 7, 73.
124. J. Mercader, E. Wanecq, J. Chen, C. Carpene. Isopropylnorsynephrine is a stronger lipolytic agent in human adipocytes than synephrine and other amines present in Citrus aurantium. J. Physiol. Biochem. 2011, 67, 443.
125. W. G. Anderson. The sympathomimetic activity of N-isopropyloctopamine in vitro. J. Pharmacol. Exp. Ther. 1983, 225, 553.
126. A. M. Lands, J. I. Grant. The vasopressor action and toxicity of cyclohexylethylamine derivatives. J. Pharmacol. Exp. Ther. 1952, 106, 341.
127. J. Lee, B. Venhuis, S. Heo, H. Choi, I. Seol, E. Kim. Identification and quantitation of N,-diethylphenethylamine in preworkout supplements sold via the Internet. Forensic Toxicol. 2014, 32, 148.
128. J. Xu, Q.-B. Han, S.-L. Li, X.-J. Chen, X.-N. Wang, Z.-Z. Zhao, H.-B. Chen. Chemistry, bioactivity and quality control of Dendrobium, a commonly used tonic herb in traditional Chinese medicine. Phytochem. Rev. 2013, 12, 341.
129. P. A. Cohen, J. C. Travis, B. J. Venhuis. A methamphetamine analog (N,alpha-diethyl-phenylethylamine) identified in a mainstream dietary supplement. Drug Test. Anal. 2014, 6, 805.
130. M. A. ElSohly, W. Gul. LC-MS-MS analysis of dietary supplements for N-ethyl-alpha-ethyl-phenethylamine (ETH), N, N-diethylphenethylamine and phenethylamine. J. Anal. Toxicol. 2014, 38, 63.
131. R. Wahlstrom, C. Styles, G. Hagglund. Reliable identification and quantification of three diethylphenethylamines in a Dendrobium-based dietary supplement. Anal. Methods. 2014, 6, 7891.
132. M. A. ElSohly, T. P. Murphy, K. M. ElSohly, W. Gul. LC-MS-MS analysis of N,alpha-Diethylphenethylamine (N,alpha-ETH) and Its positional isomer N,beta-Diethylphenethylamine (N,beta-ETH) in dietary supplements. J. Anal. Toxicol. 2015, 39, 387.
133. V. Uralets, M. App, S. Rana, S. Morgan, W. Ross. Designer phenethylamines routinely found in human urine: 2-ethylamino-1-phenylbutane and 2-amino-1-phenylbutane. J. Anal. Toxicol. 2014, 38, 106.
134. CDC, Overweight and Obesity. Available at: http://www.cdc.gov/obesity/data/facts.html [23 June 2015].
135. W. R. Hiatt, A. Thomas, A. B. Goldfine. What cost weight loss? Circulation. 2012, 125, 1171.
136. J. L. Pillitteri, S. Shiffman, J. M. Rohay, A. M. Harkins, S. L. Burton, T. A. Wadden. Use of dietary supplements for weight loss in the United States: results of a national survey. Obesity (Silver Spring). 2008, 16, 790.
137. I. G. Jacobson, J. L. Horton, B. Smith, T. S. Wells, E. J. Boyko, H. R. Lieberman, M. A. Ryan, T. C. Smith. Bodybuilding, energy, and weight-loss supplements are associated with deployment and physical activity in U.S. military personnel. Ann. Epidemiol. 2012, 22, 318.
138. S. H. Kim, J. Lee, T. Yoon, J. Choi, D. Choi, D. Kim, S. W. Kwon. Simultaneous determination of anti-diabetes/anti-obesity drugs by LC/PDA, and targeted analysis of sibutramine analog in dietary supplements by LC/MS/MS. Biomed. Chromatogr. 2009, 23, 1259.
139. R. Hachem, M. Malet-Martino, V. Gilard. First identification and quantification of lorcaserin in an herbal slimming dietary supplement. J. Pharm. Biomed. Anal. 2014, 98, 94.
140. Food and Drug Administration. NADA 140-973 Ventipulmin® Syrup - original approval. Available at: http://www.fda.gov/animalveterinary/products/approvedanimaldrugproducts/foiadrugsummaries/ucm054881.htm [29 June 2015].
141. J. J. Choo, M. A. Horan, R. A. Little, N. J. Rothwell. Anabolic effects of clenbuterol on skeletal muscle are mediated by beta 2-adrenoceptor activation. Am. J. Physiol. 1992, 263E50.
142. M. K. Parr, K. Koehler, H. Geyer, S. Guddat, W. Schänzer. Clenbuterol marketed as dietary supplement. Biomed. Chromatogr. 2008, 22, 298.
143. S. Guddat, G. Fussholler, H. Geyer, A. Thomas, H. Braun, N. Haenelt, A. Schwenke, C. Klose, M. Thevis, W. Schänzer. Clenbuterol - regional food contamination a possible source for inadvertent doping in sports. Drug Test. Anal. 2012, 4, 534.
144. H. A. Spiller, K. J. James, S. Scholzen, D. J. Borys. A descriptive study of adverse events from clenbuterol misuse and abuse for weight loss and bodybuilding. Subst. Abus. 2013, 34, 306.
145. C. Pulce, P. Saviuc, X. Pineau, V. Gibaja, O. Bidault. Clenbuterol: Retrospective study of cases from the French Poison and Toxicovigilance centres between 2000 and 2008. Clin. Toxicol. 2011, 49, 215.
146. J. Brett, A. H. Dawson, J. A. Brown. Clenbuterol toxicity: a NSW poisons information centre experience. Med. J. Aust. 2014, 200, 219.
147. S. Garattini, S. Cactia, T. Mennini, R. Samanin, S. Consolo, H. Ladinsky. Biochemical pharmacology of the anorectic drug fenfluramine: a review. Curr. Med. Res. Opin. 1979, 6, 15.
148. J. E. Blundell, C. J. Latham, E. Moniz, R. A. McArthur, P. J. Rogers. Structural analysis of the actions of amphetamine and fenfluramine on food intake and feeding behaviour in animals and in man. Cur. Med. Res. Opin. 1979, 6, 34.
149. H. M. Connolly, J. L. Crary, M. D. McGoon, D. D. Hensrud, B. S. Edwards, W. D. Edwards, H. V. Schaff. Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med. 1997, 337, 581.
150. D. J. Graham, L. Green. Further cases of valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med. 1997, 337, 635.
151. Food and Drug Administration. FDA Announces withdrawal fenfluramine and dexfenfluramine (Fen-Phen). Available at: http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm179871.htm [23 June 2015].
152. Y. R. Ku, Y. S. Chang, K. C. Wen, L. K. Ho. Analysis and confirmation of synthetic anorexics in adulterated traditional Chinese medicines by high-performance capillary electrophoresis. J. Chromatogr. A. 1999, 848, 537.
153. S. M. Bryant, C. Lozada, M. Wahl. A Chinese herbal weight loss product adulterated with fenfluramine. Ann. Emerg. Med. 2005, 46, 208.
154. A. Nakadai, H. Inagaki, M. Minami, H. Takahashi, R. Namme, M. Ohsawa, S. Ikegami. Determination of the optical purity of N-nitrosofenfluramine found in the Chinese slimming diet. Yakugaku Zasshi. 2003, 123, 805.
155. T. Y. Chan. Potential risks associated with the use of herbal anti-obesity products. Drug Saf. 2009, 32, 453.
156. D. H. Ryan. Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity. Endocrine. 2000, 13, 193.
157. FDA. FDA Drug Safety Communication: FDA recommends against the continued use of Meridia (sibutramine). Available at: http://www.fda.gov/Drugs/DrugSafety/ucm228746.htm [23 June 2015].
158. W. P. James, I. D. Caterson, W. Coutinho, N. Finer, L. F. Van Gaal, A. P. Maggioni, C. Torp-Pedersen, A. M. Sharma, G. M. Shepherd, R. A. Rode, C. L. Renz. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N. Engl. J. Med. 2010, 363, 905.
159. Y. Li, H. Zhang, J. Hu, F. Xue, C. Sun. A GC-EI-MS-MS method for simultaneous determination of seven adulterants in slimming functional foods. J. Chromatogr. Sci. 2012, 50, 928.
160. D. J. Mans, A. C. Gucinski, J. D. Dunn, C. M. Gryniewicz-Ruzicka, L. C. Mecker-Pogue, J. L. Kao, X. Ge. Rapid screening and structural elucidation of a novel sibutramine analogue in a weight loss supplement: 11-desisobutyl-11-benzylsibutramine. J. Pharm. Biomed. Anal. 2013, 83, 122.
161. D. Muller, W. Weinman, M. Hermanns-Clausen. Chinese slimming capsules containing sibutramine sold over the Internet: a case series. Dtsch. Arztebl. Int. 2009, 106, 218.
162. J. D. Dunn, C. M. Gryniewicz-Ruzicka, D. J. Mans, L. C. Mecker-Pogue, J. F. Kauffman, B. J. Westenberger, L. F. Buhse. Qualitative screening for adulterants in weight-loss supplements by ion mobility spectrometry. J. Pharm. Biomed. Anal. 2012, 71, 18.
163. P. Phattanawasin, U. Sotanaphun, T. Sukwattanasinit, J. Akkarawaranthorn, S. Kitchaiya. Quantitative determination of sibutramine in adulterated herbal slimming formulations by TLC-image analysis method. Forensic Sci. Int. 2012, 219, 96.
164. K. Saka, K. Konuma, S. Asai, K. Unuma, M. Nakajima, K. Yoshida. Identification of active ingredients in dietary supplements using non-destructive mass spectrometry and liquid chromatography-mass spectrometry. Forensic Sci. Int. 2009, 191e5.
165. H. J. Kim, J. H. Lee, H. J. Park, S. H. Cho, S. Cho, W. S. Kim. Monitoring of 29 weight loss compounds in foods and dietary supplements by LC-MS/MS. Food Addit. Contam. Part A Chem. Anal. Control Expo. Risk Assess. 2014, 31, 777.
166. S. P. Chen, M. H. Tang, S. W. Ng, W. T. Poon, A. Y. Chan, T. W. Mak. Psychosis associated with usage of herbal slimming products adulterated with sibutramine: a case series. Clin. Toxicol. (Phila.). 2010, 48, 832.
167. P. A. Cohen, C. Benner, D. McCormick. Use of a pharmaceutically adulterated dietary supplement, Pai You Guo, among Brazilian-born women in the United States. J. Gen. Intern. Med. 2012, 27, 51.
168. Food and Drug Administration. Import Alert 66-41 Detention without physical examination of unapproved new drugs promoted in the US. Available at: http://www.accessdata.fda.gov/cms_ia/importalert_190.html [2 December 2015].
169. S. R. Smith, N. J. Weissman, C. M. Anderson, M. Sanchez, E. Chuang, S. Stubbe, H. Bays, W. R. Shanahan. Multicenter, placebo-controlled trial of lorcaserin for weight management. N. Engl. J. Med. 2010, 363, 245.
170. Food and Drug Administration. Federal Register Vol. 78, No. 89, 26701 Schedules of Controlled Substances: Placement of Lorcaserin into Schedule IV. Available at: http://www.gpo.gov/fdsys/pkg/FR-2013-05-08/pdf/2013-10895.pdf [20 November 2015].
171. Food and Drug Administration. Tainted Supplements- CDER. Available at: http://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?filter=&sortColumn=3a&sd=tainted_supplements_cder&page=1 [23 June 2015].
172. J. F. Parcher, I. A. Khan. Establishment of a 'natural' origin for phytochemicals. J. Chromatogr. A. 2015, 1406, 347.
173. H. Woo, J. W. Kim, K. M. Han, J. H. Lee, I. S. Hwang, J. Kim, S. J. Kweon, S. Cho, K. R. Chae, S. Y. Han. Simultaneous analysis of 17 diuretics in dietary supplements by HPLC and LC-MS/MS. Food Addit. Contam. Part A Chem. Anal. Control Expo. Risk Assess. 2013, 30, 209.
174. Food and Drug Administration. Medication Health Fraud. Available at: http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/MedicationHealthFraud/ [8 December 2015].
175. Food and Drug Administration. Tainted products that are marketed as dietary supplements RSS feed. Available at: http://www.fda.gov/AboutFDA/ContactFDA/StayInformed/RSSFeeds/TDS/rss.xml [08 April 2016].
176. Food and Drug Administration. The Safety Reporting Portal. Available at: https://www.safetyreporting.hhs.gov/fpsr/WorkflowLoginIO.aspx?metinstance=F00BF6A9C46629DDA06D85F9D030CA92BFCF2ABA [8 December 2015].
177. Food and Drug Administration. Dietary Supplements. Available at: http://www.fda.gov/Food/DietarySupplements/ [8 December 2015].